Content developed independently by our editors and supported by our partners. Carrington Garvin had been living the fun-packed life of a typical 21-year-old in Las Vegas—dating, working for a gaming ...

In medicine, treatment goals set by physicians might differ from patient priorities. Although normalisation of laboratory parameters is a target supported by outcomes data, patient perspectives ...

In the U.S., primary sclerosing cholangitis (PSC), an uncommon fibro-inflammatory cholestatic liver disease that attacks the biliary tree, only affects an estimated 1 to 16 people per 100,000, but the ...

Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease of uncertain etiology characterized by the destruction of the intrahepatic and/or extrahepatic ducts through ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

Seladelpar is an oral, selective peroxisome proliferator-activated receptor delta agonist. Treatment with seladelpar was associated with an improvement in cholestatis markers in patients with primary ...

Learn about Primary Sclerosing Cholangitis (PSC), its causes, symptoms, diagnosis, and treatment options. Understand how PSC ...

In recent weeks, Gilead Sciences announced Health Canada's conditional approval of LYVDELZI (seladelpar) for primary biliary ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Quantitative magnetic resonance cholangiopancreatography may help assess changes in the biliary tree ...

CNW/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the ...

—New Patents Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up To 2041— —Further Expands ...